SG11202110615TA - Heterocyclic compounds and uses thereof - Google Patents
Heterocyclic compounds and uses thereofInfo
- Publication number
- SG11202110615TA SG11202110615TA SG11202110615TA SG11202110615TA SG11202110615TA SG 11202110615T A SG11202110615T A SG 11202110615TA SG 11202110615T A SG11202110615T A SG 11202110615TA SG 11202110615T A SG11202110615T A SG 11202110615TA SG 11202110615T A SG11202110615T A SG 11202110615TA
- Authority
- SG
- Singapore
- Prior art keywords
- heterocyclic compounds
- heterocyclic
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831665P | 2019-04-09 | 2019-04-09 | |
| PCT/US2020/027297 WO2020210375A1 (en) | 2019-04-09 | 2020-04-08 | Heterocyclic compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110615TA true SG11202110615TA (en) | 2021-10-28 |
Family
ID=72748693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110615TA SG11202110615TA (en) | 2019-04-09 | 2020-04-08 | Heterocyclic compounds and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11332473B2 (en) |
| EP (1) | EP3952877A4 (en) |
| JP (1) | JP2022526831A (en) |
| KR (1) | KR20210150476A (en) |
| CN (1) | CN113939296A (en) |
| AU (1) | AU2020271837A1 (en) |
| BR (1) | BR112021019703A2 (en) |
| CA (1) | CA3136492A1 (en) |
| CL (1) | CL2021002521A1 (en) |
| EA (1) | EA202192746A1 (en) |
| IL (1) | IL287026A (en) |
| MX (1) | MX2021012418A (en) |
| SG (1) | SG11202110615TA (en) |
| WO (1) | WO2020210375A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3694861A4 (en) | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| WO2023280180A1 (en) * | 2021-07-05 | 2023-01-12 | 微境生物医药科技(上海)有限公司 | Fused ring compound as wee-1 inhibitor |
| CN117751122A (en) * | 2021-08-11 | 2024-03-22 | 微境生物医药科技(上海)有限公司 | 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one compounds as Wee-1 inhibitors |
| CN117940430A (en) * | 2021-09-22 | 2024-04-26 | 微境生物医药科技(上海)有限公司 | 1, 2-Dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one compounds as Wee-1 inhibitors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003201885B2 (en) | 2002-01-18 | 2007-08-30 | Kyorin Pharmaceutical Co., Ltd. | Fused bicyclic pyrimidine derivatives |
| KR101099409B1 (en) | 2003-06-06 | 2011-12-27 | 아렉시스 악티에볼라그 | Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer |
| EP1812429A4 (en) | 2004-09-29 | 2010-07-21 | Portola Pharm Inc | Substituted 2h-1,3-benzoxazin-4(3h)-ones |
| PE20080695A1 (en) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | DIHYDROPIRAZOLOPYRIMIDINONE DERIVATIVES AS KINASE WEEL INHIBITORS |
| SI2168966T1 (en) | 2007-06-15 | 2017-03-31 | Msd K.K. | Bicycloaniline derivative |
| US8329711B2 (en) * | 2007-10-23 | 2012-12-11 | Msd K.K. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| EP2376494A4 (en) | 2008-12-12 | 2012-07-11 | Msd Kk | Dihydropyrimidopyrimidine derivatives |
| WO2011034743A1 (en) | 2009-09-15 | 2011-03-24 | Merck Sharp & Dohme Corp. | Preparation of crystalline forms of dihydropyrazolopyrimidinone |
| WO2013013031A1 (en) | 2011-07-19 | 2013-01-24 | Abbvie Inc. | Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase |
| CA2851640A1 (en) | 2011-10-20 | 2013-04-25 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| CN104271576A (en) | 2012-02-23 | 2015-01-07 | 艾伯维公司 | Pyridopyrimidinone inhibitors of kinases |
| AU2013352568B2 (en) | 2012-11-28 | 2019-09-19 | Merck Sharp & Dohme Llc | Compositions and methods for treating cancer |
| GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2015019037A1 (en) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| AU2016344040B2 (en) | 2015-11-01 | 2020-12-10 | The Regents Of The University Of Colorado, A Body Corporate | Wee 1 kinase inhibitors and methods of making and using the same |
| GB201612095D0 (en) | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201612092D0 (en) | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
| KR102030886B1 (en) | 2016-09-23 | 2019-10-10 | 재단법인 대구경북첨단의료산업진흥재단 | Novel imidazolyl pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient |
| AU2017359844B2 (en) | 2016-11-16 | 2021-09-30 | Impact Therapeutics (Shanghai), Inc | 8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidine-5(6H)-ketone compound |
| ES2902050T3 (en) | 2017-01-23 | 2022-03-24 | Shijiazhuang Sagacity New Drug Dev Co Ltd | 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-one derivative as Wee1 inhibitor |
| GB201703881D0 (en) | 2017-03-10 | 2017-04-26 | Almac Discovery Ltd | Pharmaceutical compounds |
| CN108623615B (en) * | 2017-03-23 | 2022-12-13 | 上海迪诺医药科技有限公司 | Macrocyclic derivatives of pyrazolo [3,4-d ] pyrimidin-3-one, pharmaceutical compositions and uses thereof |
| EP3600247A1 (en) | 2017-03-31 | 2020-02-05 | Seattle Genetics, Inc. | Combinations of chk1- and wee1 - inhibitors |
| CN110914277B (en) | 2017-07-10 | 2022-08-09 | 上海瑛派药业有限公司 | Imidazo [1,2-b ] pyrimido [4,5-d ] pyridazin-5 (6H) -one compounds and application thereof |
| MX2020001235A (en) * | 2017-08-01 | 2020-07-20 | Recurium Ip Holdings Llc | 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs. |
| WO2019037678A1 (en) | 2017-08-24 | 2019-02-28 | 上海迪诺医药科技有限公司 | Pyrazolo[3,4-d]pyrimidin-3-one derivative, pharmaceutical composition and use thereof |
| EP3694861A4 (en) | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| CA3078945A1 (en) | 2017-10-09 | 2019-04-18 | Nuvation Bo Inc. | Heterocyclic compounds and uses thereof |
| WO2019096322A1 (en) | 2017-11-20 | 2019-05-23 | 上海医药集团股份有限公司 | Pyrazolone-pyrimidine compound, preparation method therefor and application thereof |
| CN111315747B (en) | 2018-01-05 | 2023-05-02 | 四川科伦博泰生物医药股份有限公司 | Dihydropyrazolopyrimidine compound and preparation method and application thereof |
| US11479555B2 (en) * | 2018-02-23 | 2022-10-25 | Newave Pharmaceutical Inc. | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase |
| WO2019169065A2 (en) | 2018-02-28 | 2019-09-06 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of treating cancer using the same |
| MX2020009372A (en) * | 2018-03-09 | 2020-10-14 | Recurium Ip Holdings Llc | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones. |
| US20220169646A1 (en) | 2019-04-09 | 2022-06-02 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| EP3952878A4 (en) | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| US20220162229A1 (en) | 2019-04-09 | 2022-05-26 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| EP3952875A4 (en) | 2019-04-09 | 2022-12-28 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
-
2020
- 2020-04-08 BR BR112021019703A patent/BR112021019703A2/en not_active Application Discontinuation
- 2020-04-08 JP JP2021559854A patent/JP2022526831A/en active Pending
- 2020-04-08 EP EP20787951.1A patent/EP3952877A4/en not_active Withdrawn
- 2020-04-08 US US16/843,713 patent/US11332473B2/en active Active
- 2020-04-08 MX MX2021012418A patent/MX2021012418A/en unknown
- 2020-04-08 SG SG11202110615TA patent/SG11202110615TA/en unknown
- 2020-04-08 CA CA3136492A patent/CA3136492A1/en active Pending
- 2020-04-08 CN CN202080040846.1A patent/CN113939296A/en active Pending
- 2020-04-08 AU AU2020271837A patent/AU2020271837A1/en not_active Abandoned
- 2020-04-08 EA EA202192746A patent/EA202192746A1/en unknown
- 2020-04-08 KR KR1020217036088A patent/KR20210150476A/en unknown
- 2020-04-08 WO PCT/US2020/027297 patent/WO2020210375A1/en unknown
-
2021
- 2021-09-28 CL CL2021002521A patent/CL2021002521A1/en unknown
- 2021-10-06 IL IL287026A patent/IL287026A/en unknown
-
2022
- 2022-05-12 US US17/743,061 patent/US20230118115A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230118115A1 (en) | 2023-04-20 |
| JP2022526831A (en) | 2022-05-26 |
| KR20210150476A (en) | 2021-12-10 |
| MX2021012418A (en) | 2021-11-12 |
| IL287026A (en) | 2021-12-01 |
| BR112021019703A2 (en) | 2021-12-14 |
| EA202192746A1 (en) | 2021-12-29 |
| CA3136492A1 (en) | 2020-10-15 |
| CL2021002521A1 (en) | 2022-04-29 |
| US20200325142A1 (en) | 2020-10-15 |
| WO2020210375A1 (en) | 2020-10-15 |
| EP3952877A4 (en) | 2022-12-14 |
| CN113939296A (en) | 2022-01-14 |
| US11332473B2 (en) | 2022-05-17 |
| EP3952877A1 (en) | 2022-02-16 |
| AU2020271837A1 (en) | 2021-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001340B (en) | Heterocyclic compound and use thereof | |
| EP3694861A4 (en) | Heterocyclic compounds and uses thereof | |
| ZA202106304B (en) | Heterocyclic compound and use thereof | |
| IL285178A (en) | Compounds and uses thereof | |
| EP3663281A4 (en) | Heterocyclic compound and application thereof | |
| EP3694509A4 (en) | Heterocyclic compounds and uses thereof | |
| EP3816153A4 (en) | Heterocyclic compound and use thereof | |
| GB201803568D0 (en) | Novel compounds and uses | |
| IL285177A (en) | Compounds and uses thereof | |
| IL287026A (en) | Heterocyclic compounds and uses thereof | |
| IL289617A (en) | Heterocyclic compounds | |
| IL289595A (en) | Heterocyclic compounds | |
| ZA202105752B (en) | Haloallylamine compounds and application thereof | |
| ZA201908107B (en) | Heterocyclic compound and composition containing same | |
| IL286497A (en) | Compounds and uses thereof | |
| EP3952875A4 (en) | Heterocyclic compounds and uses thereof | |
| IL277502A (en) | Compounds and uses thereof | |
| IL291499A (en) | Aza-quinoline compounds and uses thereof | |
| IL284764A (en) | Compounds and uses thereof | |
| IL276912A (en) | Heterocyclic compound and use thereof | |
| IL279483A (en) | Cyanotriazole compounds and uses thereof | |
| EP3952876A4 (en) | Heterocyclic compounds and uses thereof | |
| IL285118A (en) | Compounds and uses thereof | |
| EP4093400A4 (en) | Heterocyclic compounds and uses thereof | |
| EP3568137A4 (en) | Heterocyclic compounds and use thereof |